Heparin-induced thrombocytopenia associated with low-molecular-weight heparin: clinical feature analysis of cases and pharmacovigilance assessment of the FAERS database

被引:3
|
作者
Liu, Leping [1 ]
Zheng, Hong [2 ]
Chen, Shanshan [3 ]
Wang, Shengfeng [4 ,5 ,6 ]
Yang, Minghua [1 ,6 ,7 ]
机构
[1] Cent South Univ, Xiangya Hosp 3, Dept Pediat, Changsha, Hunan, Peoples R China
[2] Cent South Univ, Xiangya Hosp, Dept Pediat, Changsha, Hunan, Peoples R China
[3] Cent South Univ, Hunan Canc Hosp, Dept Pharm, Affiliated Canc Hosp,Xiangya Sch Med, Changsha, Hunan, Peoples R China
[4] Cent South Univ, Xiangya Hosp 3, Dept Pharm, Changsha, Hunan, Peoples R China
[5] Cent South Univ, Xiangya Hosp 3, Postdoctoral Res Stn Clin Med, Changsha, Hunan, Peoples R China
[6] Cent South Univ, Xiangya Hosp 3, MOE Key Lab Rare Pediat Dis, Changsha, Hunan, Peoples R China
[7] Cent South Univ, Xiangya Hosp 3, Hunan Clin Res Ctr Pediat Canc, Changsha, Hunan, Peoples R China
基金
中国国家自然科学基金;
关键词
low-molecular-weight heparin; heparin-induced thrombocytopenia; characteristics; treatments; pharmacovigilance; ENOXAPARIN-INDUCED THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; SKIN NECROSIS; PATIENT; RIVAROXABAN; MANAGEMENT; THROMBOSIS; ARTERIAL; FONDAPARINUX;
D O I
10.3389/fphar.2023.1247253
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH) are commonly used anticoagulants for the management of arterial and venous thromboses. However, it is crucial to be aware that LMWH can, in rare cases, lead to a dangerous complication known as heparin-induced thrombocytopenia (HIT). The objective of this study was to evaluate the pharmacovigilance and clinical features of HIT associated with LMWH, as well as identify treatment strategies and risk factors to facilitate prompt management.Methods: We extracted adverse event report data from the FDA Adverse Event Reporting System (FAERS) database for pharmacovigilance assessment. Case reports on LMWH-induced thrombocytopenia dated up to 20 March 2023 were collected for retrospective analysis.Results: Significantly elevated reporting rates of HIT were shown in adverse event (AE) data of LMWHs in the FAERS database, while tinzaparin had a higher proportional reporting ratio (PRR) and reporting odds ratio (ROR) than other LMWHs, indicating a greater likelihood of HIT. Case report analysis indicated that a total of 43 patients showed evidence of LMWH-induced thrombocytopenia with a median onset time of 8 days. Almost half of the events were caused by enoxaparin. LMWHs were mainly prescribed for the treatment of embolism and thromboprophylaxis of joint operation. Patients with a history of diabetes or surgery appeared to be more susceptible to HIT. Clinical symptoms were mostly presented as thrombus, skin lesion, and dyspnea. Almost 90% of the patients experienced a platelet reduction of more than 50% and had a Warkentin 4T score of more than 6, indicating a high likelihood of HIT. In all patients, LMWHs that were determined to be the cause were promptly withdrawn. Following the discontinuation of LMWHs, almost all patients were given alternative anticoagulants and eventually achieved recovery.Conclusion: LMWH-induced thrombocytopenia is rare but serious, with increased risk in patients with diabetes or a surgical history. Prompt recognition and management are crucial for the safe use of LMWHs.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Heparin-induced thrombocytopenia with systemic symptoms in hemodialsysis patients under low-molecular-weight heparin
    Grandvuillemin, A.
    Rabec, M.
    Demaistre, E.
    Zanetta, G.
    Matesan, R.
    Millot, A.
    Sgro, C.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2010, 24 : 75 - 76
  • [22] Heparin-induced thrombocytopenia with thrombotic complications during prophylactic treatment with low-molecular-weight heparin
    deRaucourt, E
    Vinsonneau, C
    Juvin, K
    Fischer, AM
    Meyer, G
    BLOOD COAGULATION & FIBRINOLYSIS, 1996, 7 (08) : 786 - 788
  • [23] LOW-MOLECULAR-WEIGHT HEPARIN INDUCED THROMBOCYTOPENIA
    TARDY, B
    PAGE, Y
    TARDYPONCET, B
    COMTET, C
    ZENI, F
    BERTRAND, JC
    THERAPIE, 1990, 45 (05): : 453 - 453
  • [24] Risk for heparin-induced thrombocytopenia. with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis
    Martel, N
    Lee, J
    Wells, PS
    BLOOD, 2005, 106 (08) : 2710 - 2715
  • [25] HEPARIN-ASSOCIATED THROMBOCYTOPENIA TREATMENT WITH LOW-MOLECULAR-WEIGHT HEPARIN
    VITOUX, JF
    MATHIEU, JF
    RONCATO, M
    FIESSINGER, JN
    AIACH, M
    THROMBOSIS AND HAEMOSTASIS, 1986, 55 (01) : 37 - 39
  • [26] Low-molecular-weight heparin-associated multiple digital necrosis in a patient as a result of heparin-induced thrombocytopenia syndrome
    Kabakas, Fatih
    Ugurlar, Meric
    Ugurlar, Ozge Yapici
    Bicer, Yesim
    NORTHERN CLINICS OF ISTANBUL, 2021, 8 (04) : 402 - 404
  • [27] Heparin-induced thrombocytopenia with acute aortic and renal thrombosis in a patient treated with low-molecular-weight heparin
    Chevalier, J
    Ducasse, E
    Dasnoy, D
    Puppinck, P
    EUROPEAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY, 2005, 29 (02) : 209 - 212
  • [28] Low molecular weight heparin-induced thrombocytopenia and thrombosis
    Peters, FPJ
    Doevendans, PAFM
    Erdkamp, FLG
    VanDerEnt, FWC
    DeHeer, F
    EUROPEAN JOURNAL OF HAEMATOLOGY, 1996, 56 (05) : 329 - 330
  • [29] Low molecular weight heparins and heparin-induced thrombocytopenia
    Mammen, EF
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 1999, 5 : S72 - S75
  • [30] Low-molecular-weight heparin and thrombocytopenia
    Silver, D
    VASCULAR SURGERY, 1997, 31 (04): : 409 - 411